

Index

Note: Page numbers in italics refer to figures; page numbers in bold refer to tables

Abbreviations

- cGVHD – chronic graft-versus-host disease
- GVHD – graft-versus-host disease
- HSCT – hematopoietic stem cell transplantation

A

- abdominal pain 281, 283
 - activities, posttransplant 335–336
 - acute graft-versus-host disease
 - gastrointestinal *see* gastrointestinal graft-versus-host disease
 - hepatic *see* hepatic graft-versus-host disease
 - acute infections
 - gastrointestinal 280–281
 - late-onset, allogeneic-HSCT recipients 23
 - see also* infections
 - acute lymphoblastic leukemia (ALL)
 - neurocognitive outcomes in children following treatment 207
 - see also* leukemia
 - acute myeloid leukemia
 - treatment-related (t-AML) 35, 66, 67
 - see also* leukemia; myeloid malignancies
 - acyclovir, prevention of cytomegalovirus infection 107
 - adefovir therapy, hepatitis B virus infection **296**
 - adenovirus infections 108–109
 - adjustment, psychosocial *see* psychosocial adjustment issues
 - adult height, effects of HSCT 204
 - adults
 - health-related quality of life 345–360
 - assessment 352, **353–354**, 355–356
 - global 347
 - interventions 356, **359**
 - physical function 347–348
 - posttrauma growth 351–352
 - psychological function 348
 - social and role functioning 350
 - survivors of childhood cancer, transition from pediatric care 13–14
 - adverse health outcomes, caregivers 341–342
 - after-cataract 165
 - age, as risk factor for secondary malignancy 69
 - alcohol-based hand gels 132
 - aldosterone antagonists, hypertension management 273, **273**
 - alemtuzumab 318
 - alendronate **155**
 - alkylating agents
 - gonadal effects
 - females 194–195
 - males 183, 184, 196
 - interactions with antiretroviral medications 301
 - see also specific alkylating agents*
 - allied health professionals 17, 17–18, 52–54
 - allogeneic hematopoietic stem cell transplantation 3
 - follow-up 333
 - HIV-infected patients 300, 301
 - indications 8, 8, 9
 - late effects 4–5, 21–28
 - common nonrelapse late effects **22**, 23–27
 - dynamics of etiology 21, 22
 - future directions 28
 - identification 22–23
 - very late effects **22**, 27–28
 - see also* chronic graft-versus-host disease (cGVHD); *specific complications*
 - posttransplant routines and guidelines 332–339, **339**
 - sun exposure following 336–337
 - transplant data and trends 8, 8, 8, 9, 9
- amantadine 121, 133
- ambulatory blood pressure monitoring 270–271
- American Society of Blood and Marrow Transplantation, bronchiolitis obliterans syndrome screening recommendations 143
- angiotensin-converting enzyme inhibitors (ACEIs) 273, **273**

- angiotensin receptor blockers (ARBs) 273, **273**
- angular cheilitis 174–175, 176
- animal models, chronic graft-versus-host disease 88
- anorexia 282–283
- anthracycline cardiotoxicity 33, 244, 245, 246, 246–247
- antifungal prophylaxis
 - Aspergillus* infection 109–110
 - Candida* infection 109
- antigen detection tests, influenza diagnosis 120
- antihypertensive drugs 253, 272–273, **273**
- antineoplastic therapies, previous, as risk factor for secondary malignancy 69
- antioxidant supplementation 328
- antiretroviral therapy 300–301
- antithymocyte globulins 318
 - side effects 318
 - gastrointestinal 277, **277**
- antiviral prophylaxis
 - cytomegalovirus infection 107, 108
 - hepatitis B virus infection 295
 - herpes simplex virus infection 108
 - influenza 133
 - varicella zoster virus infection 108, 134–135
- antiviral treatment
 - hepatitis B virus infection **296**, 296–297
 - hepatitis C virus infection 298–299, **299**
 - influenza 120–121
 - Aspergillus* infection 107, 109–110
- asplenia, functional, susceptibility to bacterial infections 106
- assisted reproduction techniques 185
 - outcomes 198–199
- atherosclerosis 46, 248, 249, 250
- autoantibodies, in chronic graft-versus-host disease **78**, 88, 89, 90–91
- autoimmune thyroiditis 228–229
- autologous cell mobilization method, as risk factor for secondary malignancy 70

- autologous hematopoietic stem cell transplantation
 follow-up 332–333
 history 31
 HIV-infected patients 300, 301
 immunosuppressive therapy 315–316
 indications 8, 8, 9
 late effects 31–38, 32
 cardiac 33, 244, 245
 cognitive dysfunction 38
 endocrine 33–35
 psychologic 35, 37–38
 pulmonary 32–33
 secondary malignancies 35
 see also specific complications
 posttransplant routines and guidelines 332–339, 339
 transplant data and trends 8, 8, 8–9, 31
 autologous serum eye drops 168
 avascular necrosis *see* osteonecrosis
 azithromycin
 bronchiolitis obliterans syndrome prophylaxis/treatment 144
 organizing pneumonia treatment 146
 azoospermia 184, 196
 risk prediction 196, 197
- B**
 bacillus Calmette–Guerin vaccine 135
 bacterial infections
 late-onset 23, 106–107, 107
 risk factors and common pathogens 106, 107
 basal cell carcinoma (BCC) 27, 48–49
 B cells
 role in chronic graft-versus-host disease 43–44, 88–89
 role in human papillomavirus (HPV) infection 236
 benefit, perceptions of 351–352
 beta-blocker therapy, hypertension 273, 273
 bile acid sequestrants
 dyslipidemia management 263–264, 264, 266
 effect on blood glucose 220
 biliary disease 283
 biomarkers, chronic graft-versus-host disease 90–91, 91
 biopsy
 fine-needle aspiration (FNAB), thyroid nodules 230
 gastrointestinal 279–280
 kidney 308
 liver 287, 288
 bird feces, avoidance 338
 bisphosphonates 45–46, 153, 154, 155
 side effects 153, 176, 180
 BK virus (BKV) infection 107, 109
 bleeding, rectal 281, 283
 blood pressure
 classification 272, 272
 elevated *see* hypertension
 monitoring 251, 252, 270–271, 271
 normal, definition 269
 bocavirus, human (HBoV) 124
 boceprevir therapy, hepatitis C virus infection 299, 299
 body composition alterations 324
 pediatric patients 205
 body weight changes 323–324
 bone 151
 bone complications 45–46, 151–157
 allogenic HSCT 26
 autologous HSCT 34
 bone loss *see* bone loss
 osteonecrosis *see* osteonecrosis
 vitamin D deficiency *see* vitamin D deficiency
 bone loss 45–46, 151–154
 autologous-HSCT recipients 34
 allogenic-HSCT recipients vs. 152
 management 153–154, 155
 monitoring 152
 prevalence 152
 prevention 45–46, 152–153
 bone mineral density (BMD)
 evaluation 152, 205
 pediatric post-HSCT patients 205–206
 bone turnover markers (BTMs) 152, 154
 bortezomib 315
 breast cancer, post-HSCT 27
 bronchiolitis, lymphocytic 142, 142
 bronchiolitis obliterans syndrome (BOS) 26, 141–145
 clinical presentation 142
 diagnostic criteria 142–143
 management 144–145
 pathologic findings 142, 142
 prevention 143–144
 prognosis 141–142
 risk factors 142
 bronchoscopy, organizing pneumonia 146
 busulfan
 gastrointestinal effects 277, 277
 gonadal toxicity, females 195
- C**
 calcineurin inhibitors 316
 drug interactions 316, 386
 monitoring 316
 toxicity 316
 nephrotoxicity 305–306
 see also cyclosporine; tacrolimus
 calcitriol 153, 154
 calcium 327
 dietary sources 153, 154
 supplementation 327–328
 calcium intake, bone loss prevention 152–153
 cancer survivors
 adult survivors of childhood cancer, transition from pediatric care 13–14
 long-term, late cardiac complications 244–245
 cancer survivorship 11, 12
 cancer survivorship programs 11–14
Candida infection 107, 109
 oral 174–178, 178
 cardiac complications, late 244–247
 cancer survivors 244–245
 post-HSCT 245–247
 allogenic HSCT 244, 245
 autologous HSCT 33, 244, 245
 monitoring and management 60, 247
 pediatric patients 245
 cardiotoxicity
 anthracycline 33, 244, 245, 246, 246–247
 cyclophosphamide 33, 245
 fludarabine 245
 iron-induced 246
 cardiovascular disease, post-HSCT 46, 247–253
 autologous HSCT 33
 monitoring and management of at-risk patients 60, 250–253, 251
 posttransplant diabetes mellitus and 221–222
 risk factors *see* cardiovascular risk factors
 role of endothelial injury in pathogenesis 46, 248–249, 250
 cardiovascular risk factors (CVRs) 27, 46, 248, 250, 251
 prevention and treatment 251, 252–253
 screening 250, 251, 252
 caregiver(s) 340–343
 distress *see* caregiver distress
 education *see* caregiver education
 gender-based differences in caregiving experiences 342
 psychosocial adjustment issues 368–371
 coping with stress 368–370
 intimacy 370–371
 caregiver distress 340, 341–343, 350
 assessment 343
 causes 342
 gender-based differences 342
 impact 343
 caregiver education
 infection control measures 131
 role of allied health professionals 52–53
 care plan, survivorship 381–382, 382
 carfilzomib 315
 caries, dental 174, 177–178
 cataracts 25, 44–45, 162, 164, 164–165
 children 164, 165
 prevention and management 164, 165
 risk factors 44, 162, 164, 164–165
 secondary 165
 cat feces, avoidance 338
 central nervous system (CNS), graft-versus-host disease 26
 cerebrovascular disease 248
 cervical cancer 71, 236
 surveillance/prevention 71, 72, 236, 237, 238

- cervical cytology testing 236, 237, 238
- chemotherapy effects
gastrointestinal
abdominal pain 281
nausea and vomiting 278
gonadal function *see* gonadal function, chemoradiotherapy effects
- chest radiographs
bronchiolitis obliterans syndrome 143
organizing pneumonia 146
- chickenpox vaccine 134
- children *see* pediatric HSCT recipients
- cholangitis lenta 289
- cholecalciferol 155, 156, 327
- cholera vaccine 135
- cholesterol
total, measurement 260
see also hypercholesterolemia
- cholestyramine 263, 266
- chronic graft-versus-host disease (cGVHD) 5, 22, 43–49
animal models 88
biomarkers 90–91, 91
body composition alterations 324
cardiovascular 27, 46
see also cardiovascular disease, post-HSCT
cutaneous *see* cutaneous chronic graft-versus-host disease
gastrointestinal *see* gastrointestinal graft-versus-host disease
genital 25
see also female genital tract graft-versus-host disease
hepatic *see* hepatic graft-versus-host disease
incidence 43
nonmalignant late effects 44–46
see also specific effects
ocular *see* ocular graft-versus-host disease
oral *see* oral chronic graft-versus-host disease
pathogenesis 43–44, 88–90, 89, 90
pulmonary 45, 141
see also pulmonary complications, late-onset
secondary malignant disease and 24, 27, 44, 48–49, 70–71
see also late effects
- chronic infections
allogenic-HSCT recipients 23–24
gastrointestinal 282–283
see also infections
- chronic kidney disease (CKD), post-HSCT 25, 304–311
classification 309
definition 307
epidemiology 304–305
etiology 305–306
evaluation 307–308, 308
general considerations 310–311
management 308–310
choice of renal replacement therapy 309
kidney transplantation 309–310
need for integral patient care 311
prognosis of decline in renal function 308–309, 309
- chronic obstructive pulmonary disease 45
- church attendance, posttransplant 334
- cirrhosis 109, 290, 296, 297, 298
- clinic blood pressure measurement 270
- Clostridium difficile* infection 106–107
- cognitive development *see* pediatric HSCT recipients
- cognitive dysfunction, autologous-HSCT vs. allogenic-HSCT recipients 38
- colesevelam 263–264, 264, 266
- colestipol 263, 266
- community respiratory viral (CRV) infections 116–124, 131
prevention 116–117, 131–133
infection containment 117, 131–132
postexposure prophylaxis 132–133
see also specific infections/pathogens
- complementary and alternative medicine (CAM) therapies, hepatotoxicity 24
- conditioning-induced oral mucositis 277–278
- conditioning regimen
gastrointestinal effects 277, 277
as risk factor for secondary malignancy 70
see also total body irradiation (TBI)
- congestive heart failure (CHF) 33, 245, 246, 246
doxorubicin-induced 244
cooking 338–339
- coronary artery disease 248
risk, calcium intake and 152–153
- coronavirus, human (HCoV) 124
- corticosteroids *see* steroid therapy
- counseling
clinic follow-up visit, recommendations 383, 383
fertility 199, 199–200
see also patient education
- crowded places, avoidance 334
- cryopreservation
embryo 199–200
sperm *see* sperm cryopreservation
- cryptogenic organizing pneumonia (COP) 145, 145
- cutaneous chronic graft-versus-host disease 24, 77–100, 249
animal models 88
biomarkers 90–91, 91
clinical management 93–99
role of skin sclerosis score 94, 95
steroid-refractory cGVHD 97–99, 98, 99
systemic treatment 96–99, 98
topical therapy 94–96, 95
- clinical manifestations and evolution 78–87, 79
dyschromial lesions 79, 79, 82, 82, 83–84
lichen-planus-like lesions 79, 79, 82
onset 78, 80–81
sclerosis 79, 82, 85–86, 86–87, 87
histopathology 91–93
eosinophilic fasciitis 93
lichenoid cGVHD 91, 92
National Institutes of Health (NIH) pathology consensus 93, 94
sclerodermiform cGVHD 91, 92, 93
National Institutes of Health (NIH) diagnostic criteria 77, 93, 94
nonsclerotic 78
pathogenesis 88–90, 89, 90
sclerotic-type 77–78, 78
systemic sclerosis vs. 77, 78
- cutaneous complications
allogenic HSCT 24
GVHD *see* cutaneous chronic graft-versus-host disease
see also specific complications
- cyclophosphamide
cardiotoxicity 33, 245
gastrointestinal effects 277, 277
gonadal toxicity, females 195
- cyclosporine 316
as cause of dyslipidemia 259
eye drops 168
role in posttransplant diabetes mellitus pathogenesis 217
- cytarabine, gastrointestinal effects 277, 277
- cytokines, fibrogenic, role in chronic graft-versus-host disease 44, 88, 89, 89–90
- cytomegalovirus (CMV) infection 107, 107–108
prophylaxis 107–108
retina 164, 169
- cytotoxic agents 318–319
see also specific cytotoxic agents
- D
- daily routines, posttransplant 334
- DAS181 (Fludase) 121, 123–124
- DASH (Dietary Approaches to Stop Hypertension) eating plan 272
- denileukin diftitox 318
- dental caries 174, 177–178
- dental/periodontal complications 26, 173, 177–179
dental decay 174, 177–178
desquamative gingivitis 178
drug-induced gingival overgrowth 179
periodontitis 178–179
- depression, caregivers 341
- desquamative gingivitis 178
- diabetes mellitus, posttransplant *see* posttransplant diabetes mellitus (PTDM)

- diarrhea 278–281, 282–283
 acute gastrointestinal graft-versus-host disease 278–279, **279**
 chronic gastrointestinal graft-versus-host disease 282, 282
 infection-associated 280
 medication-induced 281
- diet, neutropenic 338
- dietary modifications
 diabetes management 219
 hyperlipidemia management 253, 263
 hypertension management 253, 272
- dietary sources
 calcium 153, **154**
 vitamin D 155
- dietary supplementation *see* supplement use
- dipeptidyl peptidase-4 (DPP-4) 220, **221**
- distress, caregivers *see* caregiver distress
- diuretics, hypertension management 272–273, **273**
- driving 337, **339**
- drug-induced liver injury (DILI) 289
- drug interactions
 antiretroviral therapy 301
 calcineurin inhibitors 316, **386**
 mycophenolate mofetil 317
 sirolimus therapy 317
 statins-immunosuppressant agents 265–266
- drug-related complications *see* medication-induced complications
- drug resistance, 2009 H1N1 (2009H1N1v) influenza virus 118, 119, 121
- drugs, transplant-related **386**
see also specific drugs
- dry eye syndrome 25, **164**, 165–168
 prevention and management 167–168
see also ocular graft-versus-host disease
- dual-energy X-ray absorptiometry (DXA) 152, 153
- dyschromial lesions, cutaneous chronic graft-versus-host disease 79, **79**, 82, 82, 83–84
- dyslipidemia *see* hyperlipidemia, post-HSCT
- dysmotility 281
- dysphagia 278, 281–282
- E**
- eating out, precautions 338–339
- education
 caregiver *see* caregiver education
 patient *see* patient education
- embryo cryopreservation 199–200
- endemic infections, allogenic-HSCT recipients 23
- endocrine complications
 late
 allogenic HSCT 25
 autologous HSCT 33–35
 recommendations for screening and prevention **62**
- treatment, effect on cardiovascular risk 262
see also specific complications
- endoscopy, acute gastrointestinal graft-versus-host disease 279, **279**
- endothelial injury, role in cardiovascular disease pathogenesis 46, 248–249, 250
- end-stage renal disease (ESRD) 304
 treatment 309–310
see also chronic kidney disease (CKD), post-HSCT
- entecavir therapy, hepatitis B virus infection **296**, 297
- eosinophilic fasciitis 93
- epiphyseal growth plate (EGP) 203–204
- Epstein-Barr virus (EBV) infection 107, 108
 management 72, 73, 108
 posttransplant lymphoproliferative disorder association 47, 66, **67**, 71, 108
 viral load monitoring 71–72, 108
- erectile dysfunction
 causes 189–190
 treatment 190–191, **191**
- ergocalciferol 155, 156, 327
- erythematous candidiasis 174
- esophagus
 chronic graft-versus-host disease 25, 281–282
 infections 282
 secondary malignancy 282
- etanercept 318
- etoposide, gastrointestinal effects 277, 277
- European Group for Blood and Marrow Transplantation (EBMT)
 annual activity survey 7–10
 registry 11
- everolimus therapy, cutaneous chronic graft-versus-host disease 99
- exercise 335–336
 fall prevention 153
- extracorporeal photopheresis (ECP)
 bronchiolitis obliterans syndrome 144
 steroid-refractory cGVHD 97–98, **98**
- eye
 anatomy 163
 complications *see* ocular complications
- eye drops, dry eye syndrome/ocular graft-versus-host disease management 168
- eye shielding, during total body irradiation 165
- ezetimibe 263, **264**
- F**
- fall prevention 153
- family members
 caregivers *see* caregiver(s)
 relationship issues 369–370
 role in prevention of infectious complications 334–335
- vaccinations, influenza 108, 122, 133, 334–335
- family members, exposure to 130–135
- infections 130–133
 prevention strategies 131–133, 333–334
 recent live vaccinations 133–135, 333
- fasciitis, eosinophilic 93
- fasting plasma glucose (FPG)
 measurement 217, 217–218
- fatty liver disease, non-alcoholic 291
- favipiravir 121
- female caregivers, caregiving experiences 342
- female fertility, post-HSCT 193–196, 238–239
 effects of chemoradiotherapy 194–195, 238–239
 management of fertility issues 195–196
 preservation and counseling 199, 199–200
see also pregnancy, post-HSCT
- female genital tract graft-versus-host disease 25, 233–236
 clinical evaluation 234–235
 differential diagnosis 235
 incidence and risk factors 233–234
 severity scoring 234, **234**
 treatment and prevention 235–236
- female gonadal function, chemoradiotherapy effects 194–195, 238–239
- female HSCT recipients 233–240
 care and screening recommendations **237**
 fertility *see* female fertility, post-HSCT
- genital GVHD *see* female genital tract graft-versus-host disease
- gonadal failure *see* ovarian failure
- gonadal function, chemoradiotherapy effects 194–195, 238–239
- HPV infection *see* human papillomavirus (HPV) infection
- return to work 372
- fenofibrate **264**, 265
- fertility, post-HSCT
 allogenic-HSCT recipients 26
 autologous-HSCT recipients 34
 female *see* female fertility, post-HSCT
 male *see* male fertility, post-HSCT
 preservation and counseling 199, 199–200, 239
see also infertility
- fibric acid derivatives **264**, 265
- fibrogenic cytokines, role in chronic graft-versus-host disease 44, 88, 89, 89–90
- fibrovascular polyp, oral 173
- fine-needle aspiration biopsy (FNAB), thyroid nodule 230
- fludarabine
 cardiotoxicity 245
 gastrointestinal effects 277, 277
- Fludase (DAS181) 121, 123–124

- follicle-stimulating hormone (FSH)
 measurement
 females 195
 males 185, 187, 197
 follow-up 332–333
 children *see* pediatric HSCT recipients
 dyslipidemia 266
 need for 379
see also long-term follow-up
 foodborne illnesses, avoidance 338
 food habits 338–339
 Fracture Risk Assessment Tool (FRAX)
 151
 fractures 45, 151, 152
 friends
 role in prevention of infectious
 complications 334–335
see also family members
 fructosamine 218
 functional asplenia, susceptibility to bacterial
 infections 106
 fungal exposure, home environment 335
 fungal infections
 late-onset 106, 107, 109–110
 allogenic-HSCT recipients 23
 pneumonia 335
 risk factors and common pathogens 106,
 107, 109
- G**
 gadolinium, kidney disease and 310–311
 galactomannan 110
 gastroesophageal reflux disease 282
 gastrointestinal complications 24–25,
 276–283
 acute/subacute 277–281
 chronic 281–283
 GVHD *see* gastrointestinal graft-versus-host
 disease
 infections *see* gastrointestinal infections
 preconditioning-related 276–277, 277
see also oral complications; *specific
 complications*
 gastrointestinal conditions,
 preexisting 276–277
 gastrointestinal graft-versus-host disease
 acute 278–281
 concomitant infections 280–281
 endoscopy 279, 279
 grading 279, 279
 histology 279–280, 280
 radiology 280
 symptoms 278–279, 279
 chronic 24–25, 281–282
 esophagus 25, 281–282
 scoring 282
see also oral chronic graft-versus-host
 disease
 future directions 283
 gastrointestinal infections
 acute 280–281
 chronic 282–283
 gastroparesis 282
 gemfibrozil 264, 265
 gender, as risk factor for secondary
 malignancy 69
 gender-based differences, caregiving
 experiences 342
 general health, post-HSCT 352
 genital complications 25
see also female genital tract graft-versus-host
 disease
 gingival overgrowth, drug-induced 179
 gingivitis, desquamative 178
 global health-related quality of life 347
 glomerular filtration rate (GFR),
 estimation 307
 glomerular proteinuria 307, 308
 glucagon-like peptide-1 (GLP-1) 220, 221
 glucocorticoids
 effect on insulin action 217, 217
see also steroid therapy
 glucose tolerance, impaired (IGT) 216, 218
 glucose tolerance test, oral (OGTT) 217,
 218
 glycemic targets, posttransplant diabetes
 mellitus 220
 gonadal damage
 autologous HSCT 34
see also hypogonadism
 gonadal function, chemoradiotherapy effects
 females 194–195, 238–239
 males 183–184
 graft characteristics, as risk factor for
 secondary malignancy 70
 graft-versus-host disease (GVHD)
 acute
 gastrointestinal *see* gastrointestinal
 graft-versus-host disease
 hepatic *see* hepatic graft-versus-host
 disease
 central nervous system 26
 chronic *see* chronic graft-versus-host disease
 (cGVHD)
 sun exposure and 336
 Graves' disease 228
 group therapy 373
 growth, children *see* pediatric HSCT
 recipients
 growth, posttraumatic 351–352
 growth hormone 204
 growth hormone deficiency 249, 252
 growth hormone therapy 205, 252
 effect on cardiovascular risk 252
 guidelines
 long-term follow-up *see* long-term
 follow-up
 National Marrow Donor Program (NMDP)/
 Be The Match 379–380, 382
 posttransplant routines and activities
 332–339, 339
 screening/preventive practices 57, 59–63,
 64, 379, 384
see also long-term follow-up, guidelines
 guilt, survival 373
 gynecologic surveillance 71, 235–236, 237,
 238
- H**
 hand hygiene 132, 333, 334, 338
 health-promoting behaviors, post-HSCT
 352
 health-related quality of life
 (HRQL) 345–360
 adults *see* adults
 assessment 352, 353–355, 355–356
 autologous-HSCT recipients 37
 children *see* pediatric HSCT recipients
 effects of HSCT process and
 procedure 346
 future perspectives 359, 360
 general health and health-promoting
 behaviors 352
 global 347
 interventions 356, 358, 359–360
 online resources 356, 357
 physical function 347–348
 psychological function 348–350
 social and role functioning 350–351
see also quality of life (QOL)
 height, effects of HSCT 204
 hematologic malignancies 47
 allogenic-HSCT recipients 28
 autologous-HSCT recipients 35, 36–37
see also myeloid malignancies;
 posttransplant lymphoproliferative
 disorders (PTLDs)
 hematopoietic stem cell transplantation
 (HSCT)
 allogenic *see* allogenic hematopoietic stem
 cell transplantation
 autologous *see* autologous hematopoietic
 stem cell transplantation
 indications 8, 8, 9
 transplant data and trends 3, 7–10,
 8, 8, 9
 hemochromatosis, secondary 24
 hepatic complications 24, 286–292
 acute 287–289
 chronic 290–292
 GVHD *see* hepatic graft-versus-host
 disease
 initial evaluation 286–287, 287
 screening and prevention 60
see also specific complications
 hepatic graft-versus-host disease
 acute 287–288
 diagnosis 287–288
 treatment 288
 chronic 24, 290
 diagnosis 290
 dyslipidemia and 259
 treatment 290
 hepatic veno-occlusive disease 288–289
 hepatitis B immunization 295
 hepatitis B virus (HBV) 294

- hepatitis B virus (HBV) infection 109,
290–291, 294–297
diagnosis 290, 290–291
epidemiology 294
management 291, 296, 296–297
patients with active infection 291, 296,
296–297
patients with indeterminate
infection 297
patients with resolved infection 297
post-HSCT complications 295–296
pre-transplant evaluation 290, 290, 295
prevention 295
reverse seroconversion 290, 295–296
- hepatitis C virus (HCV) 297
- hepatitis C virus (HCV) infection 109, 291,
297–299
epidemiology 297
post-HSCT complications 298
pre-transplant evaluation 291, 297–298
treatment 298–299, 299
- hepatocellular carcinoma (HCC) 109, 298
- herbal preparations 329
- herpes simplex virus (HSV) infection 107, 108
- herpes simplex virus (HSV) reactivation 108,
176, 176
- highly active antiretroviral therapy 300
- hip fracture 151
- histopathology
acute gastrointestinal GVHD 279–280, 280
cutaneous cGVHD *see* cutaneous chronic
graft-versus-host disease
organizing pneumonia 145, 145
- HIV-infected patients, stem cell
transplantation 299–301
allogenic 300, 301
autologous 300, 301
historical experience 299–300
practical considerations 300–301
- HMG-CoA reductase inhibitors *see* statins
- Hodgkin disease, posttransplant 47
- home blood pressure monitoring 271
- home environment, posttransplant
considerations 335
- hormone replacement therapy (HRT),
post-HSCT 46, 152, 153, 195, 239
effect on cardiovascular risk 252
- human bocavirus (HBoV) 124
- human coronavirus (HCoV) 124
- human immunodeficiency virus infection *see*
HIV-infected patients, stem cell
transplantation
- human metapneumovirus (HMPV) 116, 124,
131
- human papillomavirus (HPV) infection,
females 236–238
clinical evaluation and current screening
guidelines 236–238, 237
incidence and risk factors 236
pathogenesis 236
prevention 238
secondary malignancy association 71, 236
- human papillomavirus (HPV)
vaccination 72, 238
- human parainfluenza virus (HPIV) 116,
123–124, 131
- human rhinovirus (HRhV) 124
- Hurler syndrome 204
- 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors *see*
statins
- hypercholesterolemia
mechanisms 259
prevalence and incidence 258–259
see also hyperlipidemia, post-HSCT
- hyperferritinemia 291, 328
- hyperleptinemia 249
- hyperlipidemia, post-HSCT 248, 251,
258–266
diabetes and 221–222
follow-up 266
management 251, 253, 260–265, 261, 264
Adult Treatment Panel III
guidelines 253, 262, 262
pharmacologic therapy 253, 263–265,
264
mechanisms 259–260
prevalence and incidence 258–259
screening and evaluation 251, 252, 260,
261
- hyperprolactinemia 187
- hypertension
definition 269
post-HSCT 248, 251, 269–274
diabetes and 221–222, 269–270
incidence and prevalence 269–270
long-term implications 271–272
risk factors 270
screening 251, 252, 270–271, 271
treatment 251, 253, 272–273
workup 271, 271
see also cardiovascular disease, post-HSCT
- hyperthyroidism 226, 228–229
causes 228–229
evaluation and treatment 229
risks 228
signs and symptoms 228
subclinical 35
- hypertriglyceridemia
prevalence and incidence 258, 259
see also hyperlipidemia, post-HSCT
- hypogammaglobulinemia 132, 315
- hypoglycemia, diabetes management and 220
- hypoglycemic agents, oral 219–220, 221
- hypogonadism
allogenic-HSCT recipients 25–26
autologous-HSCT recipients 34
metabolic syndrome and 249
see also male hypogonadism; ovarian failure
- hypomagnesemia 249, 328–329
- hypothyroidism 25, 35, 226, 226–228, 249
cardiovascular risk and 249, 252
evaluation 227–228
management 227–228, 252
- pregnancy-related 226, 230
risks 227
signs and symptoms 227
subclinical 35, 225, 226
- I
- ibandronate 155
- idiopathic pneumonia syndrome (IPS) 32
- IGF-1 (insulin-like growth factor-1) 204–205
- imatinib
antifibrotic effect 89–90, 90
cutaneous chronic graft-versus-host disease
management 89–90, 90, 99, 99
- immunizations *see* vaccinations
- immunofluorescence, influenza diagnosis
120
- immunosuppressive therapy 314–319
autologous HSCT 315–316
complications 316–319
dyslipidemia 259–260, 263
nephrotoxicity 305–306
oral 180
secondary malignancy 70–71
- interactions
antiretroviral therapy 301
statin therapy 265–266
- monitoring 314–319
autologous HSCT 315–316
general recommendations 314–315
need for long-term immunosuppressive
agents 315
see also specific immunosuppressive agents
- impaired glucose tolerance (IGT) 216, 218
- infections
bacterial *see* bacterial infections
fungal *see* fungal infections
gastrointestinal *see* gastrointestinal
infections
late-onset 106–110
allogenic-HSCT recipients 23–24
recommendations for screening and
prevention 59
oral 174–177, 278
prevention/control measures 116–117,
131–132, 333–334
community respiratory viral infections
see community respiratory viral
(CRV) infections
considerations in home
environment 335
role of family and friends 334–335
risk factors and common pathogens 106,
107, 130
viral *see* viral infections
see also specific infections/pathogens
- infectious esophagitis 282
- infertility
allogenic-HSCT recipients 25–26
autologous-HSCT recipients 34
female 193, 238–240
management 195–196
see also female fertility, post-HSCT

- preventive measures and counseling 199, 199–200
 recommendations for screening and prevention 63
see also fertility, post-HSCT; hypogonadism; male fertility, post-HSCT
- inflammation, role in post transplant diabetes mellitus 216–217
- infliximab 318
- influenza 116, 117–122, 131
 complications 118
 diagnostics 119–120
 pandemic 2009H1N1v infection 118–119, 121
 prevention 121–122, 133
 symptoms 118
 transmission 117–118
 treatment 120–121
- influenza vaccination 108, 110, **110**, 121–122, 133, **339**
 close contacts and family members 108, 122, 133, 334–335
- influenza vaccine, live attenuated (LAIV) 135
- influenza virus (IFV) 117
- informal caregivers *see* caregiver(s)
- inhaled corticosteroid therapy, bronchiolitis obliterans syndrome 144
- insulin, effect of glucocorticoids 217, 217
- insulin-like growth factor-1 204–205
- insulin resistance 216, 217, 249
- insulin therapy, posttransplant diabetes mellitus 219
- intellectual functioning, pediatric HSCT recipients 208, 209
 evaluation 208
- interactions *see* drug interactions
- interferon (IFN) therapy, hepatitis C virus infection 298–299, **299**
- intimacy issues 370–371
- intravenous immunoglobulin (IVIG), prophylactic 132, 315
- iron-induced cardiotoxicity 246
- iron overload 291, 328
- J**
- JC virus (JCV) infection 107, 109
- joints, complications 45–46
see also bone complications
- K**
- keratoconjunctivitis sicca 25, 45, 166
see also dry eye syndrome
- kidney
 biopsy 308
 complications *see* renal complications
 function, assessment 307–308, 308
 transplantation 309–310
- Krabbe's disease 209
- L**
- laboratory assessments, nutritional status 325
- lactation issues, allogenic-HSCT recipients 26
- lamivudine therapy, hepatitis B virus infection 296, **296**
- large intestinal strictures 283
- laser therapy, cataracts 165
- late acute graft-versus-host disease, gastrointestinal 282
- late effects 4–5, **59–63**
 allogenic HSCT *see* allogenic hematopoietic stem cell transplantation
 autologous HSCT *see* autologous hematopoietic stem cell transplantation
 definition 21
 resources and guidance 5
 timelines 4
see also chronic graft-versus-host disease (cGVHD); long-term follow-up; *specific complications*
- learning *see* pediatric HSCT recipients
- left ventricular ejection fraction (LVEF)
 dysfunction 33, 245
 monitoring 247
- lenalidomide 315
- leptin 249
- leukemia
 acute lymphoblastic, neurocognitive outcomes in children following treatment 207
 post-HSCT 28, 47, 66, 67
 treatment, effect on gonadal function 184
- libido, HSCT effects
 female 240
 male 188–189
- lichenoid cutaneous cGVHD 91, 92
- lichenoid lesions, oral mucosal cGVHD 172–173, 174
- lichen planus-like cGVHD 79, 79, 82
- lichen sclerosis-like cGVHD 79, 82, 85, 93
- lifestyle modifications
 hyperlipidemia management 253, **262**, 263
 hypertension management 272
 posttransplant diabetes mellitus management 219, 253
- linear growth, effects of HSCT 203–205
- lipid monitoring 251, 252, 260
- lipoprotein X 259
- live attenuated influenza vaccine (LAIV) 135
- liver biopsy 287, 288
- liver injury
 drug-induced 289
 markers 286–287, **287**
 patterns 287, **287**
see also hepatic complications
- LIVESTRONG Care Plan 381–382
- live vaccinations, family members 133–135, 333
- living donor kidney transplantation 310
- long-term follow-up
 calendar 381–384
 components 16, 17
- guidelines 5, 57–58, **59–63**, 64
 areas for future research 58, 64
 screening/preventive practices 57–58, **59–63**, 64, 379, 384
 utilization 58
- kidney function 307–308
- lessons from cancer survivorship models 12–14
- organization of visit 382–384, **383**
 clinic follow-up 383, **383**
 post-clinic follow-up 383–384
 preparation for visit 382–383
 role of allied health professionals 52–54
- long-term follow-up transplant clinic
 addressing sexual issues 371
 annual visits 18, 53–54
 first visit 53
 functions 16–17, 17
 models 15, **16**
 set up 12, 14–19, **19**
 team composition 17, 17–18
- long-term survivors 3–4, 9–10
 caregivers *see* caregiver(s)
 definition 12
 health-related quality of life *see* health-related quality of life (HRQL)
- late complications *see* late effects
 resources and guidance 5
see also long-term follow-up, guidelines
 support groups *see* support groups
- transplant-related medications **386**
see also specific medications
- transplant survivorship programs 12
see also long-term follow-up
- low density lipoprotein (LDL) cholesterol levels, measurement 260
- lung transplantation, end-stage bronchiolitis obliterans syndrome 145
- luteinizing hormone (LH) measurement
 females 195
 males 187, 197
- lymphocytic bronchiolitis 142, 142
- lymphomas 47
 treatment, effect on gonadal function 184
see also posttransplant lymphoproliferative disorders (PTLDs)
- M**
- magnesium deficiency 249, 328–329
- magnesium supplementation 328–329
- magnetic resonance imaging (MRI), osteonecrosis monitoring 157
- male caregivers, caregiving experiences 342
- male fertility, post-HSCT 184–185, 196–197
 assessment 185
 azoospermia risk, prediction 196, 197
 chemotherapy and radiotherapy effects 184, 196
 management of fertility issues 197
 preservation and counseling 199, 199–200
- male gonadal function, chemoradiotherapy effects 183–184, 196

- male hypogonadism 34, 183–188
 causes 183–184, **184**
 definition 183
 diagnosis of testosterone deficiency
 185–187, **186**
 secondary 187, 188
 symptoms and signs 186, **186**
 testosterone replacement therapy *see*
 testosterone replacement therapy
- male patients, return to work 372
- mammalian target of rapamycin (mTOR)
 inhibitors, cutaneous chronic
 graft-versus-host disease
 management 99
- mammograms 71
- masks, infection control/prevention 117,
 131–132, 333–334, **339**
- measles, mumps, rubella (MMR) vaccine
 134
- mechanical treatments, erectile
 dysfunction 190–191, **191**
- mediastinal radiotherapy, cardiac
 complications 245
- medication-induced complications
 hepatic 289
 nausea, vomiting, and diarrhea 281,
 283
 oral 179–180
- medications, transplant-related **386**
see also specific medications
- meglitinides 220, **221**
- meibomian gland dysfunction 166
- melphalan
 cardiotoxicity 33
 gastrointestinal effects 277
- metabolic syndrome 218, 221, 249, 252
- metformin 219–220, **221**
- methotrexate 318
- microvascular retinopathy **164**, 168–169
- mineral supplementation 328–329
- MMR (measles, mumps, rubella) vaccine
 134
- mobile app resources, National Marrow Donor
 Program (NMDP)/Be The
 Match 379–380
- montelukast therapy, bronchiolitis obliterans
 syndrome 144
- mouse models, chronic graft-versus-host
 disease 88
- mucocutaneous complications
 cutaneous chronic graft-versus-host
 disease 87
 recommendations for screening and
 prevention **62**
see also cutaneous chronic graft-versus-host
disease
- mucosal atrophy, oral 173
- mucosal carcinoma 48–49
- mucosal complications, oral *see* oral
 complications
- multivitamin supplementation 325–326, 329,
329
- musculoskeletal complications 26
 affecting oral cavity 173, 179
 recommendations for screening and
 prevention **61**
see also bone complications
- mycophenolate mofetil 317
 drug interactions 317
 role in posttransplant diabetes mellitus
 pathogenesis 217
 side effects 317
 steroid-refractory cGVHD
 management 97, **98**, 317
- myelodysplastic syndrome, treatment-related
 (t-MDS) 35, 66, 67
- myeloid malignancies 35, 47, **66**, 66–67
 incidence 68
 pathogenesis, autologous vs. allogenic
 HSCT 66–67
- N**
- National Cancer Institute, Common
 Terminology for Adverse Events
 Criteria 277, **277**
- National Institutes of Health (NIH) diagnostic
 criteria
 bronchiolitis obliterans syndrome 142–143
 cutaneous chronic graft-versus-host
 disease 77, 93, **94**
- National Marrow Donor Program
 (NMDP) 18
- National Marrow Donor Program (NMDP)/Be
 The Match guidelines resource 379–
 380, 382
- nausea 278–281, 282–283
 acute gastrointestinal graft-versus-host
 disease 278
 chronic gastrointestinal graft-versus-host
 disease 282, 282
 medication-induced 281
 post-chemotherapy 278
- nephrogenic systemic fibrosis 310
- nephropathy, polyoma BK
 virus-associated 306
- nephrotic syndrome 306
- nephrotoxic drugs, avoidance in CKD 311
- nephrotoxicity, immunosuppressive
 therapy 305–306
- neuraminidase inhibitors 120–121
- influenza chemoprophylaxis 133
 resistance 117, 118, 119, 121
- neurocognitive outcomes, children *see* pediatric
 HSCT recipients
- neurologic complications, late
 allogenic HSCT 26–27
 recommendations for screening and
 prevention **61**
- neutropenic diet 338
- niacin 264, **264**
- Nocardia* infection 106
- nodular regenerative hyperplasia 291–292
- nodules, thyroid 225, **226**, 229–230
- non-alcoholic fatty liver disease 291
- non-Hodgkin's lymphoma 66, 315
 patient's perspective 376–378
- non-nucleoside reverse transcriptase inhibitors
 (NNRTIs), drug interactions 301
- non-sclerotic cutaneous chronic graft-versus-
 host disease 78
- non-steroidal topical therapy, cutaneous
 chronic graft-versus-host disease 95, **95**
- nutritional problems, prevalence 323–324
- nutritional supplements *see* supplement use
- nutrition assessments 325
- nutritionists, role of 373
- O**
- obesity 249
 sarcopenic 205
- obliterating bronchiolitis *see* bronchiolitis
 obliterans syndrome (BOS)
- ocular anatomy 163
- ocular complications 44–45, 162–169, **164**
 cataracts *see* cataracts
 dry eye syndrome *see* dry eye syndrome
 GVHD *see* ocular graft-versus-host disease
 posterior segment 162, **164**, 168–169
 recommendations for screening and
 prevention **59**
- ocular graft-versus-host disease 162, 165–168
 acute 166
 chronic 25, 44–45, 166
 staging 167, **167**
 diagnosis 166
 pathogenesis 166
 prevention and management 167–168
- odynophagia 278, 281–282
- office blood pressure measurement 270
- omega-3 fatty acids **264**, 264–265
- online patient resources 356, **357**, 358
 National Marrow Donor Program (NMDP)/
 Be The Match 379–380
- oocytes
 effects of chemoradiotherapy 194
 freezing 200
 programmed cell death 194
- oral candidiasis 174–178, **178**
- oral chronic graft-versus-host disease 24, 172
 assessment instruments 173, **175**
 mucosal 24, 172–173, **174**
 management 173, **178**
- oral complications 24, 172–180, **173**,
 277–278
 acute/subacute 277–278
 dental/periodontal *see* dental/periodontal
 complications
- epidemiology 172
- malignancy 173, 174, 179
- medication-related 179–180
- mucosal 172–177, **173**, 277–278
 infectious 174–177, 278
 non-infectious 172–174, **174**
see also oral chronic graft-versus-host
disease; oral mucositis
- musculoskeletal disturbances 173, 179

- recommendations for screening and prevention **59**
see also salivary gland complications
 oral glucose tolerance test (OGTT) **217, 218**
 oral hypoglycemic agents **219–220, 221**
 oral mucositis
 conditioning-induced **277–278**
 infectious **278**
 see also oral complications, mucosal
 oral pain **277–278, 281**
 oral polio vaccine (OPV) **134**
 oral typhoid vaccine **135**
 organizing pneumonia (OP) **145–146**
 histologic findings **145, 145**
 oropharyngeal dysphagia **281**
 oseltamivir **121, 133**
 resistance **118, 119, 121**
 osteomalacia **154**
 osteonecrosis **26, 45, 156–157**
 management **45, 157**
 monitoring **157**
 prevalence **45, 156–157**
 prevention **157**
 osteonecrosis of the jaw, bisphosphonate-related **153, 176, 180**
 osteopenia **26, 45, 151**
 prevalence **152**
 see also bone loss
 osteoporosis **34, 45–46, 151**
 prevalence **152**
 see also bone loss
 ovarian failure **194–195, 238–239**
 indicators **195**
 management **195–196**
 ovarian tissue banking **200**
 overlap syndrome
 cutaneous GVHD **93**
 gastrointestinal GVHD **278, 282**
- P**
 pain
 abdominal **281, 283**
 management, quality of life and **374**
 oral **277–278, 281**
 rectal **281, 283**
 palivizumab (PVZ) **122**
 pancreatic disease **283**
 pandemic 2009 H1N1 influenza virus **118–119, 121**
 parental psychological function **349–350**
 Passport for Care **382**
 patient education
 follow-up visit recommendations **383, 383**
 infection control measures **131**
 role of allied health professionals **52–53**
 Patient-Generated Subjective Global Assessment (PG-SGA) **325**
 patient outcomes, caregiver distress and **342, 343**
 patient resources, online *see* online patient resources
 patient satisfaction **374**
 patient's perspective, support groups **376–378**
 PDGF (platelet-derived growth factor), role in chronic graft-versus-host disease **89, 89**
 pediatric cancer care, transition to adult long-term care **13–14**
 pediatric HSCT recipients
 cardiac complications **245**
 cataracts **164, 165**
 cognitive development and learning **206–210**
 areas in need of further research **210**
 HSCT-related factors that may affect cognitive development **206–207**
 methodological issues in transplant research with neurocognitive outcomes **207–208**
 post-HSCT neurocognitive functioning **208–209**
 growth **203–206**
 body composition **205**
 bone mineral density **205–206**
 linear **203–205**
 recommendations **206**
 health-related quality of life **345–360**
 assessment **354–355, 356**
 global **347**
 interventions **356, 358, 359–360**
 physical function **348**
 posttrauma growth **351–352**
 psychological function **349**
 social and role functioning **350–351**
 hypertension, incidence and prevalence **269–270**
 psychological complications **207, 210, 349**
 penile graft-versus-host disease **25**
 penile prostheses **190–191**
 pentostatin **97, 98, 318–319**
 peramivir **119, 121**
 periodontal complications *see* dental/periodontal complications
 periodontitis **178–179**
 pets **337–338**
 phosphodiesterase-5 inhibitors **190, 191**
 phototherapy, cutaneous chronic graft-versus-host disease **95, 96**
 physical function **347–348**
 platelet-derived growth factor (PDGF), role in chronic graft-versus-host disease **89, 89**
 pneumococcal vaccination **110, 110**
Pneumocystis jiroveci **107, 110**
 pneumonia
 coronavirus **124**
 fungal **335**
 human parainfluenza virus **123**
 as influenza complication **118**
 organizing *see* organizing pneumonia (OP)
 Pneumocystis **110**
 respiratory syncytial virus **122**
 polyoma BK virus-associated nephropathy (PVAN) **306**
 polyomavirus-associated hemorrhagic cystitis (PVHC) **109**
 polyomaviruses **109**
 pomalidomide **315**
 posterior capsular opacification **165**
 posterior chamber, eye
 anatomy **163**
 complications **162, 164, 168–169**
 postexposure prophylaxis, respiratory viruses **132–133**
 post-HSCT late effects *see* late effects
 posttransplant diabetes mellitus (PTDM) **25, 215–222, 248, 251**
 co-morbidities **220–222**
 hypertension **221–222, 269–270**
 management **219–220, 251, 253**
 monitoring **218, 251, 252**
 pathogenesis **216–217**
 prevalence **215–216**
 prevention **218–219**
 risk factors **216**
 screening and diagnosis **217, 217–218, 252**
 posttransplant follow-up *see* follow-up
 posttransplant lymphoproliferative disorders (PTLDs) **28, 47, 65–66, 66, 108**
 classification **66, 67**
 clinical presentation **65–66**
 abdominal pain **281**
 Epstein–Barr virus association **47, 66, 67, 71, 108**
 oral **179**
 patients at high risk of **71, 71**
 treatment **72–73**
 posttransplant risk factors, secondary malignancies **69, 70–71**
 posttransplant routines and guidelines **332–339, 339**
 see also specific activities
 posttraumatic growth (PTG) **351–352**
 posttraumatic stress disorder (PTSD)
 adults **348**
 children **349**
 parents **349–350**
 pregnancy, post-HSCT **198–199, 238–239**
 allogenic-HSCT recipients **26**
 autologous-HSCT recipients **34**
 see also fertility, post-HSCT
 pregnancy-related hypothyroidism **226, 230**
 prehypertension **272**
 management **273**
 pretransplant risk factors, secondary malignancies **69, 69–70**
 preventive practices, guidelines **57–58, 59–63, 64, 379, 384**
 see also long-term follow-up, guidelines
 proctitis, radiation **283**
 profibrotic cytokines, role in chronic graft-versus-host disease **44, 88, 89, 89**
 programmed cell death (PCD), oocytes **194**
 prostaglandin E1 (PGE1), erectile dysfunction treatment **190, 191**
 protease inhibitors, drug interactions **301**

- proteinuria
 nephrotic range 306
 screening 307, 308
- pseudomembranous oral candidiasis 174, 176
- psoralen plus ultraviolet A (PUVA)
 phototherapy, cutaneous chronic graft-versus-host disease 95, 96
- psychological complications
 adults 348
 allogenic HSCT 27
 autologous HSCT 35, 37–38
 children 207, 210, 349
 management 372–373
 recommendations for screening and prevention 63
- psychological function,
 posttransplant 348–350
 adults 348
 children 349
 parents 349–350
- psychosocial adjustment issues 368–374
 coping with stress in long-term care setting 368–370
 facing intimacy issues 370–371
- psychosocial factors, cognitive changes in HSCT patients 207
- pulmonary complications, late-onset 45
 allogenic HSCT 26, 141–147
 bronchiolitis obliterans syndrome *see* bronchiolitis obliterans syndrome (BOS)
 organizing pneumonia *see* organizing pneumonia (OP)
 autologous HSCT 32–33
 recommendations for screening and prevention 59
- pulmonary function tests (PFTs)
 bronchiolitis obliterans syndrome (BOS) 143, 144
 organizing pneumonia 146
- pulmonary rehabilitation, bronchiolitis obliterans syndrome 141–145
- Q
- quality of life (QOL) 345–346
 autologous-HSCT recipients 35, 37–38
 definition 345
 health-related *see* health-related quality of life (HRQL)
- questionnaires
 assessment of health-related quality of life 352, 353–354, 355
 nutrition screening 325
- R
- radiation proctitis 283
- radio-contrast media, acute kidney injury risk 310
- radiology, acute gastrointestinal graft-versus-host disease 280
- radiotherapy
 cardiac complications 245
 cardiovascular complications 249, 250
 effects on gonadal function *see* gonadal function, chemoradiotherapy effects
- real-time polymerase chain reaction (RT-PCR), influenza diagnosis 120
- rectal bleeding 281, 283
- rectal pain 281, 283
- reduced-intensity conditioning (RIC), late effects 167
- relationship issues 369–370
- relaxation techniques 373
- renal complications 25, 251, 304–311
 screening and prevention 61
see also chronic kidney disease (CKD), post-HSCT
- renal function, assessment 307–308, 308
- renal replacement therapy 309
- resources, online *see* online patient resources
- respiratory syncytial virus (RSV)
 infections 116, 122–123, 131
 management 123
 prevention 122–123
- respiratory viruses 107, 108, 131
see also community respiratory viral (CRV) infections
- restrictive lung disease 45
- retinopathy 164, 168–169
- return to work 371–372
- reverse seroconversion, hepatitis B 290, 295–296
- rhinovirus, human (HRhV) 124
- ribavirin therapy
 hepatitis C virus infection 298, 299, 299
 respiratory syncytial virus infection 123, 132–133
- rimantadine 133
- risedronate 155
- rituximab therapy 318
 autologous HSCT 315–316
 monitoring 318
 posttransplant lymphoproliferative disorders 72, 73, 108
 side effects 318
 steroid-refractory chronic graft-versus-host disease 98, 98–99
- role functioning, HSCT effects 350–351
- rotavirus vaccine 134
- routines, posttransplant 334
- S
- salivary gland complications 173, 177, 281
 management 177, 178
- sarcopenic obesity 205
- sclerodermiform cutaneous cGVHD 91, 92, 93
see also cutaneous chronic graft-versus-host disease
- sclerosis, cutaneous chronic graft-versus-host disease 79, 82, 85–86, 86–87, 87
- sclerotic-type cutaneous chronic graft-versus-host disease (ScGVHD) 77–78, 78
 manifestations at onset 78, 80–81
see also cutaneous chronic graft-versus-host disease
- screening practices, guidelines 57–58, 59–63, 64, 379, 384
see also long-term follow-up, guidelines
- screening questionnaires, nutrition 325
- seasonal virus infections 116–124, 131
 preventing disease 117
 preventing exposure 116–117
see also specific infections
- secondary malignancies 46–49, 65–73
 allogenic-HSCT recipients 27–28
 autologous-HSCT recipients 35, 36–37
 chronic graft-versus-host disease and 24, 27, 44, 48–49, 70–71
- esophagus 282
- incidence 68
- models 65–68, 66
- myeloid *see* myeloid malignancies
- oral 173, 174, 179
- PTLDs *see* posttransplant lymphoproliferative disorders (PTLDs)
- risk factors 46–47, 68–71, 69
 posttransplant 70–71
 pretransplant 69–70
 transplant factors 70
 solid *see* solid malignancies
- surveillance and prevention 71–72
 recommendations 62
 therapeutic strategies 72–73
- self-examination, secondary malignancy surveillance 71
- semen analysis 185, 197
- serologic testing, influenza diagnosis 120
- severe combined immune deficiency (SCID), effect of HSCT on neurocognitive functioning 209
- sexual activity, posttransplant recommendations 336
- sexual activity and function, HSCT effects
 men 188–189, 190
 women 190, 239–240
see also sexual dysfunction
- sexual dysfunction
 allogenic-HSCT recipients 27
 autologous-HSCT recipients 34
 females 240
 males 189
see also erectile dysfunction
- recommendations for screening and prevention 63
see also hypogonadism
- sexual relationships, intimacy issues 370–371
- shingles vaccine 134
- sildenafil 190, 191
- sinusoidal obstruction syndrome 288–289
- sirolimus therapy 317–318
 cutaneous chronic graft-versus-host disease 98, 99

- drug interactions 317
 monitoring 317–318
 side effects 317
 dyslipidemia 260
- Sjögren-like syndrome 166
- skin cancer, post-HSCT 27, 48–49
- skin chronic graft-versus-host disease *see*
 cutaneous chronic graft-versus-host
 disease
- skin complications
 allogenic HSCT 24
 GVHD *see* cutaneous chronic graft-versus-
 host disease
 see also specific complications
- skin sclerosis score 94, 95
- smallpox (vaccina) vaccine 135
- social complications, allogenic-HSCT 27
- social functioning, HSCT effects 350–351
- socioeconomic status (SES), cognitive
 outcomes and 209, 220908
- solid malignancies 47–49, **66**, 68
 allogenic-HSCT recipients 27
 autologous-HSCT recipients 35, **36**, **37**
 incidence 68
 pathogenesis 47–48
 see also secondary malignancies
- sperm analysis 185, 197
- sperm cryopreservation 185, 197, 200
- fatherhood rates 198
- spiritual issues 374
- squamous cell carcinoma (SCC) 27, 48–49
 oral 174, 179
- statins 253, 263, **264**
 interaction with immunosuppressant
 agents 265–266
 side effects 263, 265
- stem cell sources 3–4, 9, 346
 posttransplant recovery and 346
- steroid-induced hyperglycemia 217
- steroid-refractory chronic graft-versus-host
 disease, management 97–99, **98**, 99
- steroid therapy 316
 bronchiolitis obliterans syndrome 144
 cataract formation and 44, 165
 chronic graft-versus-host disease 316
 chronic graft-versus-host disease, cutaneous
 systemic 96–97
 topical 94–95, **95**
- effect on insulin action 217, 217
- female genital tract graft-versus-host
 disease 235
- monitoring 316
- organizing pneumonia 146
- side effects 316
 bone loss 151
 dyslipidemia 259
- stress, coping with 368–370
- strictures, large intestinal 283
- subacute non-suppurative cholangitis 289
- subclinical hypothyroidism 35, 225, 226
- Subjective Global Assessment (SGA) 325
- sulfonylureas 219, 220, **221**
- sun exposure 336–337, **339**
- sunscreen application 336, 337
- supplement use 325–329
 antioxidants 328
 calcium 327–328
 herbal preparations 329
 minerals 328–329
 multivitamins 325–326
 recommendations 329, **329**
 vitamin D 155, 156, 326–327
- support groups 369
 patient's perspective 376–378
- surgical management, cataracts 165
- surgical masks, infection control 117,
 131–132, 333–334, **339**
- survival guilt 373
- survivors, long-term *see* long-term survivors
- survivorship care plan 381–382, **382**
- survivorship programs, cancer 11–14
- swimming 336
- systemic sclerosis, cutaneous chronic
 graft-versus-host disease *vs.* 77, **78**
- T**
- tacrolimus 316
 dyslipidemia association 260
 role in posttransplant diabetes mellitus
 pathogenesis 217
 steroid-refractory cGVHD
 management **98**
- tadalafil 190, **191**
- T** cells
 role in chronic graft-versus-host
 disease 43, 44, 88
 role in human papillomavirus
 infection 236
 role in post transplant diabetes
 mellitus 216–217
- telaprevir therapy, hepatitis C virus
 infection 299, **299**
- telbivudine therapy, hepatitis B virus
 infection **296**
- tenofovir therapy, hepatitis B virus
 infection **296**, 297
- teriparatide 153, 154, **155**
- testosterone deficiency
 diagnosis 185–186, **186**, 186
 see also male hypogonadism
- testosterone replacement therapy 187–188,
 188, 197
 effect on cardiovascular risk 252
- thalassemia patients, post-HSCT 204, 205,
 206
 iron-induced cardiotoxicity 246
- thalidomide 315
- therapeutic lifestyle modification *see* lifestyle
 modifications
- thiotepa, gastrointestinal effects 277,
 277
- thrombotic microangiopathy,
 transplantation-associated 305
- thyroid cancer 27, 49, 229, 230
- thyroid disease 225–230, **226**
 allogenic-HSCT recipients 25
 autologous-HSCT recipients 35
 hyperthyroidism *see* hyperthyroidism
 hypothyroidism *see* hypothyroidism
 pregnancy and **226**, 230
- thyroidectomy 230
- thyroid hormone replacement therapy 227,
 228
- thyroid nodules 225, **226**, 229–230
- thyroid stimulating hormone (TSH)
 levels 225
 hypothyroidism 227
- thyrotoxic periodic paralysis 228
- Ticket to Work program 372
- TNF (tumor necrosis factor) inhibitors 318
- topical therapy
 cutaneous chronic graft-versus-host
 disease 94–96, **95**
 dry eye syndrome/ocular graft-versus-host
 disease 168
 genital graft-versus-host disease 235
- total body irradiation (TBI)
 cardiac complications, late 245
 cataract formation and 44, 162, 164, 165
 cognitive outcomes and 209
 eye shielding 165
 fertility effects
 females 194, 238
 males 196
 gastrointestinal effects 277, **277**
 as risk factor for posttransplant
 diabetes 216
 as risk factor for secondary malignancy 70
- total cholesterol, measurement 260
- total skin score (TSS) 94
- transforming growth factor beta (TGF- β), role
 in cutaneous chronic graft-versus-host
 disease 89
- transplantation-associated thrombotic
 microangiopathy (TA-TMA) 305
- transplant conditioning *see* conditioning
 regimen
- transplant-related mortality (TRM) 3
- transplant risk factors, secondary
 malignancies **69**, 70
- transplant survivorship programs 12
 lessons from cancer survivorship
 models 12–14
 see also long-term follow-up
- treatment-related acute myeloid leukemia
 (t-AML) 35, 66, 67
- treatment-related myelodysplastic syndrome
 (t-MDS) 35, 66, 67
- tubular proteinuria 307, **308**
- tumor necrosis factor (TNF) inhibitors 318
- type 2 diabetes
 pathogenesis 216
 see also posttransplant diabetes mellitus
 (PTDM)
- typhilitis 281
- typhoid vaccine, oral 135

- tyrosine kinase inhibitors, cutaneous chronic graft-versus-host disease management 99, 99
- U
- ultrasonography, thyroid 230
- V
- vaccinations
- family members *see* family members
 - influenza *see* influenza vaccination
 - post-HSCT 53, 54, 333, **339**
 - recommendations 110, **110**
 - pre-transplant, hepatitis B 295
- vaccina (smallpox) vaccine 135
- vaccines
- live 133–135
 - see also specific vaccines/vaccinations*
- vacuum-assisted erection devices 190
- vaginal disease, genital graft-versus-host disease 234
- vaginal scarring, management 235
- vaginal–vulvar graft-versus-host disease *see* female genital tract graft-versus-host disease
- valacyclovir, prevention of cytomegalovirus (CMV) infection 107
- Vanderbilt transplant program 372
- vardenafil 190, **191**
- varicella virus vaccines 134–135
- varicella-zoster immune globulin, human 134–135
- varicella zoster virus (VZV) infection 107, 108
- vascular complications *see* cardiovascular disease, post-HSCT
- veno-occlusive disease, hepatic 288–289
- verruciform xanthoma 173–174
- very late effects, allogenic HSCT **22**, 27–28
- see also specific complications*
- viral infections
- hepatitis 290–291
 - see also* hepatitis B virus (HBV) infection; hepatitis C virus (HCV) infection
 - late-onset 106, 107, 107–109
 - allogenic-HSCT recipients 23
 - as risk factor for secondary malignancy 71
 - risk factors and common pathogens 106, 107
 - seasonal *see* seasonal virus infections
 - see also* community respiratory viral (CRV) infections
- viral isolation, influenza diagnosis 120
- viral shedding 117, 131
- influenza virus 117
- visual imagery 373
- vitamin D 154, 326
- sources 155, 326
 - supplementation 155, 156, 326–327
- vitamin D deficiency 154–156, 326–327
- management 156, 326–327
 - monitoring 156
 - prevalence 156, 326
 - prevention 156
- vitamin supplementation
- prevalence 325–327
 - recommendations 329, **329**
- vomiting 278–281, 282–283
- acute gastrointestinal graft-versus-host disease 278
 - chronic gastrointestinal graft-versus-host disease 282, 282
 - infection-associated 280
 - medication-induced 281, 283
 - post-chemotherapy 278
- vulvar disease, genital graft-versus-host disease 234
- W
- walking, benefits 335–336
 - washing, hand 132, 333, 334, 338
 - weight changes 323–324
 - work, return to 371–372
- Worldwide Bone Marrow Transplant Group (WBMT) 7
- X
- xerostomia 177, 281
- Z
- zanamivir 118–119, 121, 133
 - zinc deficiency 328
 - zoledronic acid **155**
- Z-scores 152, 203
- pediatric HSCT recipients 204, 205, 206



